…
Aimei Health Technology Co., Ltd does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aimei Health Technology Co., Ltd (AFJK) is a U.S.-listed health-technology company focused on serving healthcare markets in China, although public disclosures offer limited operational detail. Long-term growth drivers that may benefit the company include China's aging population, rising healthcare demand and wider adoption of digital health solutions, so investors may find exposure to domestic healthcare digitization attractive if execution succeeds.
Most important investment risks include regulatory and cross-border listing uncertainty for Chinese issuers, low trading liquidity, and execution and financing risks that could materially impair operations.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 |
| Income before tax | 2.55M | 0.17M |
| Net income | 2.55M | 0.17M |
| Ebit | -1.06M | 0.17M |
| Ebitda | -1.06M | 0.17M |
| Depreciation and amortization | - | 0.20M |
| Operating income | -1.06M | -0.03M |
| Other operating expenses | 1.06M | 0.03M |
| Interest income | 3.62M | - |
| Net interest income | 3.62M | - |
| Income tax expense | 2.55M | 0.17M |
| Total revenue | 0.00M | - |
| Total operating expenses | 1.06M | 0.03M |
| Total other income expense net | 3.62M | 0.20M |
| Net income from continuing ops | 2.55M | - |
| Breakdown | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 |
| Total assets | 73.81M | 70.47M |
| Other current assets | 0.00M | - |
| Total liab | 1.51M | 0.71M |
| Total stockholder equity | 72.31M | 69.76M |
| Other current liab | 0.59M | 0.02M |
| Common stock | 73.78M | 69.89M |
| Capital stock | 73.78M | 69.89M |
| Retained earnings | -1.48M | -0.13M |
| Other assets | - | 0.00M |
| Cash | 0.03M | 0.58M |
| Total current liabilities | 0.82M | 0.02M |
| Net debt | 0.20M | -0.58M |
| Short term debt | 0.23M | - |
| Short long term debt | 0.23M | - |
| Short long term debt total | 0.23M | - |
| Other stockholder equity | -73.78M | - |
| Total current assets | 0.03M | 0.58M |
| Short term investments | - | 69.89M |
| Non currrent assets other | 73.78M | 69.89M |
| Non current assets total | 73.78M | 69.89M |
| Breakdown | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 |
| Investments | -0.28M | - |
| Total cashflows from investing activities | -0.28M | -69.69M |
| Net borrowings | 0.28M | - |
| Total cash from financing activities | 0.40M | 70.27M |
| Net income | 2.55M | 0.17M |
| Change in cash | -0.55M | 0.58M |
| Begin period cash flow | 0.58M | - |
| End period cash flow | 0.03M | 0.58M |
| Total cash from operating activities | -0.67M | - |
| Issuance of capital stock | 0.00M | - |
| Other cashflows from investing activities | -0.28M | - |
| Other cashflows from financing activities | 0.12M | 70.27M |
| Capital expenditures | 0.00M | 0.00M |
| Change in working capital | 0.39M | 0.02M |
| Other non cash items | -3.62M | -0.20M |
| Free cash flow | -0.67M | - |
Sector: Financial Services Industry: Shell Companies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| AFJK Aimei Health Technology Co., Ltd Ordinary Share |
0.36 2.99% |
12.39 | 204.00 | - | - | 5.95 |
| CLUS CLUS |
- -% |
200.00 | - | - | 0.09 | 0.92 |
| SGDH Sgd Holdings Ltd |
- -% |
0.11 | - | - | 59741.55 | 0.56 |
| LION Lionsgate Studios Holding Corp. |
-0.03 0.18% |
14.21 | - | 23.31 | 1.13 | 1.35 |
| QKIE QKIE |
0.44 29.33% |
1.94 | - | - | 470.20 | - |
Aimei Health Technology Co., Ltd does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to acquire small cap businesses in the biopharmaceutical, medical technology and device industries, as well as in the diagnostic and other services sector. Aimei Health Technology Co., Ltd was incorporated in 2023 and is based in New York, New York.
10 East 53rd Street, New York, NY, United States, 10022
861 375 8131392
| Name | Title | Year Born |
|---|---|---|
| Mr. Junheng Xie | CEO, Secretary & Director | 1989 |
| Mr. Heung Ming Wong | CFO & Director | 1970 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.